Efficacy and safety of preemptive anti-CMV therapy with valganciclovir after kidney transplantation

Clinical Transplantation

Volumn 21, Issue 1, 2007, Pages 80-85

  Lopau, Kai ^a   Greser, Alexandra ^b   Wanner, Christoph ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b Deutsche Stiftung Organtransplantation ^*  (Germany)

Author keywords

Antiviral therapy; Cytomegalovirus; Kidney transplantation; Preemptive therapy; Valganciclovir

Indexed keywords

BASILIXIMAB; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ABDOMINAL CRAMP; ACUTE GRAFT REJECTION; ADULT; AMBULATORY CARE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MONITORING; DRUG POTENCY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GASTROINTESTINAL PAIN; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; MALE; PILOT STUDY; PRIORITY JOURNAL; RELAPSE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; ANTIGENS, VIRAL; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; GANCICLOVIR; HISTOCOMPATIBILITY TESTING; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; TISSUE DONORS;

EID: 33846650508     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2006.00586.x     Document Type: Article

References (26)

1. Sia IG, Patel R. New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. Clin Microbiol Rev 2000: 13: 83.
2. Nett PC, Heisey DM, Fernandez LA, Sollinger HW, Pirsch JD. Association of cytomegalovirus disease and acute rejection with graft loss in kidney transplantation. Transplantation 2004: 78: 1036.
3. Schnitzler MA, Woodward RS, Brennan DC, Spitznagel EL, Dunagan WC, Bailey TC. Impact of cytomegalovirus serology on graft survival in living related kidney transplantation: Implications for donor selection. Surgery 1997: 121: 563.
4. Eriksson BM, Wirgart BZ, Claesson K et al. A prospective study of rapid methods of detecting cytomegalovirus in the blood of renal transplant recipients in relation to patient and graft survival. Clin Transplant 1996: 10: 494.
5. Solez K, Vincenti F, Filo RS. Histopathologic findings from 2-year protocol biopsies from a US multicenter kidney transplant trial comparing tacrolimus versus cyclosporine: A report of the FK506 Kidney Transplant Study Group. Transplantation 1998: 66: 1736.
6. Pouria S, State OI, Wong W, Hendry BM. CMV infection is associated with transplant renal artery stenosis. QJM 1998: 91: 185.
7. Hagenmeyer EG, Haussler B, Hempel E et al. Resource use and treatment costs after kidney transplantation: Impact of demographic factors, comorbidities, and complications. Transplantation 2004: 77: 1545.
8. The EBPG Expert Group on renal transplantation. European Best Practice Guidelines for renal transplantation (part 1). Nephrol Dial Transplant 2000: 15: 71.
9. Opelz G, Dohler B, Ruhenstroth A. Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: A collaborative transplant study report. Am J Transplant 2004: 4: 928.
10. Singh N. Preemptive therapy versus universal prophylaxis with ganciclovir for cytomegalovirus in solid organ transplant recipients. Clin Infect Dis. 2001: 32: 742.
11. Singh N, Paterson DL, Gayowski T, Wagener MM, Marino IR. Cytomegalovirus antigenemia directed pre-emptive prophylaxis with oral versus I.V. ganciclovir for the prevention of cytomegalovirus disease in liver transplant recipients: A randomized, controlled trial. Transplantation 2000: 70: 717.
12. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet 2000: 356: 645.
13. Pescovitz MD, Rabkin J, Merion R. Valganciclovir provides ganciclovir plasma exposure similar to IV ganciclovir in transplant recipients. Transplantation 1999: 67: 126.
14. Pescovitz MD, Rabkin J, Merion RM et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000: 44: 2811.
15. Paya C, Humar A, Dominguez E et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004: 4: 611.
16. Dekoning J, Vandorp WT, Vanes LA, Vantwout JW, V anderwoude FJ. Ganciclovir effectively treats cytomegalovirus disease after solid-organ transplantation, even during rejection treatment. Nephrol Dial Transplant 1992: 7: 350.
17. Dunn DL, Mayoral JL, Gillingham KJ et al. Treatment of invasive cytomegalovirus disease in solid organ transplant patients with ganciclovir. Transplantation 1991: 51: 98.
18. Erice A, Jordan C, Chace BA, Fletcher C, C hinnock BJ, B alfour HH. Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts. JAMA 1987: 257: 3082.
19. Noble S, Faulds D. Ganciclovir - an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 1998: 56: 115.
20. Babel N, Gabdrakhmanova L, Juergensen JS et al. Treatment of cytomegalovirus disease with valganciclovir in renal transplant recipients: A single center experience. Transplantation 2004: 78: 283.
21. Lowance D, Neumayer HH, Legendre CM et al. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med 1999: 340: 1462.
22. Preiksaitis JK, Brennan DC, Fishman J, Allen U. Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 2005: 5: 218.
23. Jung D, Dorr A. Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects. J Clin Pharmacol 1999: 39: 800.
24. Wiltshire H, Paya CV, Pescovitz MD et al. Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients. Transplantation 2005: 79: 1477.
25. Fellay J, Venetz JP, Pacual M, Aubert JD, Seudoux C, Meylan PR. Treatment of cytomegalovirus infection or disease in solid organ transplant recipients with valganciclovir. Am J Transplant 2005: 5: 1781.
26. Singh N, Wannstedt C, Keyes L, Gayowski T, Wagener MM, Cacciarelli TV. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: Impact on viral load and late-onset cytomegalovirus disease. Transplantation 2005: 79: 85.